Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



2008 Should Make or Break MannKind

With only one compound in late-stage testing and that compound's study results coming out in the next few months, 2008 will be a make-it-or-break-it year for MannKind (Nasdaq: MNKD  ) .

MannKind's only potential near-term revenue-generating drug is its inhaled insulin Technosphere, which is in multiple phase 3 studies as a treatment for both type 1 and type 2 diabetes. This year, we'll get to see a multitude of data from those phase 3 trials. If the data is good enough, an FDA marketing application for Technosphere may follow.

Top-line data from one of the upcoming pivotal efficacy studies in type 1 diabetes should be released in the third quarter, and data from a phase 3 trial testing the drug in type 2 diabetes patients is guided to be out before year's end, according to MannKind. The last of the three crucial studies MannKind needs to successfully get Technosphere onto the market is its two-year safety study, the results of which will be publicly announced either prior to MannKind's Technosphere marketing application or in conjunction with it.

Speaking of marketing application, if everything goes according to plan, MannKind is also projecting filing for approval with the FDA in 2008. This timeline puts the earliest chance for possible approval of Technosphere in the second half of 2009.

In its fourth-quarter conference call yesterday, MannKind's wonderfully successful founder and CEO Alfred Mann gave a spirited denunciation of the other inhaled insulin products like Eli Lilly's (NYSE: LLY  ) and Alkermes' (Nasdaq: ALKS  ) AIR insulin drug. We won't find out in 2008 if Technosphere is more marketable than these other inhaled insulins, but the numerous data results that will be out this year will be a good start in outlining Technosphere's potential.

Read/Post Comments (1) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 07, 2008, at 10:38 AM, codyla wrote:

    I would bet on break. I have been a type 1 diabetic for 40 years and have participated in clinical research. Unless this treatment surpasses the current treatment by FAR, I would not be willing to switch. People not taking injections seem to feel that we diabetics detest injections or being hooked up to an insulin pump, which is just not true. It's what we do and it's really no big deal. Inhaled insulin has no appeal to me at this time..... I'll stay with the current treatment.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 592950, ~/Articles/ArticleHandler.aspx, 10/26/2016 11:50:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,232.31 63.04 0.35%
S&P 500 2,143.44 0.28 0.01%
NASD 5,274.20 -9.20 -0.17%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 11:34 AM
MNKD $0.53 Up +0.00 +0.67%
MannKind CAPS Rating: *
ALKS $54.36 Down -0.10 -0.18%
Alkermes CAPS Rating: ****
LLY $77.07 Down -0.68 -0.87%
Eli Lilly and Co. CAPS Rating: ***